Abstract:OBJECTIVE To explore the therapy effects of (arginine-glycine-aspartic, RGD)(3)-truncated tissue factor (tTF) fusion protein on colorectal carcinoma in mice. METHODS The (RGD)(3)-tTF fusion gene, constructed with tTF and three series-wound peptides RGD, was expressed in Escherichia coli BL21 (DE(3)). The fusion protein was purified through Nickel affinity chromatography column. The coagulation activity of the (RGD)(3)-tTF fusion protein was detected by clotting assay in vitro. Mice colorectal cancer cells line CT26 were inoculated subcutaneously into mice to establish colorectal cancer model. Four mice were randomly divided into two groups to be injected with the (RGD)(3)-tTF or tTF fusion protein labeled with rhodamine B isothiocyanate (RBITC) at a single dose of 50 microg respectively. The location of the (RGD)(3)-tTF fusion protein in the colorectal carcinoma bearing mice tissue was analyzed by using in vivo optical imaging one hour after the injection and confocal microscopy twenty-four hours after the injection. Fifteen mice bearing colorectal carcinoma were randomly divided into three groups for injection with the (RGD)(3)-tTF, tTF fusion protein or phosphate buffered saline (PBS) at a single dose of 50 microg respectively. The tumor size was measured daily to calculate the tumor volume. Five days after the injection, the mice were killed to harvest tumor tissues, hearts, livers, spleens, lung, kidneys and brains to observe valid thrombogenesis and tumor necrosis. RESULTS With the concentration of the (RGD)(3)-tTF fusion protein increased, the clotting time was shorten correspondingly under the conditions of Ca(2+), and the clotting time was (8.6 +/- 0.2) min when the concentration was 6 micromol/L, and it was >30 min in the group of 0 micromol/L (P < 0.05). The coagulation activity of (RGD)(3)-tTF and tTF fusion protein was alike (F = 0.09, P > 0.05). The in vivo optical imaging and confocal microscopy analyses showed that RBITC fluorescence labeling (RGD)(3)-tTF fusion protein was assembled in the tumor vasculature. On the first, third, fifth day after injection, the tumor volume of (RGD)(3)-tTF fusion protein group was (120.8 +/- 4.8) mm(3), (93.8 +/- 3.4) mm(3), (132.2 +/- 7.7) mm(3) respectively, which was significantly smaller than that of the tTF group [(181.4 +/- 13.8) mm(3), (333.0 +/- 32.0) mm(3), (514.0 +/- 11.5) mm(3)] and PBS group [(182.6 +/- 11.5) mm(3), (332.8 +/- 21.0) mm(3), (524.2 +/- 16.7) mm(3)] (both P < 0.05). However, there was no significant difference in the tumor volume between the latter two groups (P > 0.05). CONCLUSION The (RGD)(3)-tTF fusion protein is capable of targeting to tumor vasculature and inducing thrombogenesis for suppressing the tumor growth in the colorectal carcinoma mice model, and it's expected to be a new therapy for colorectal cancer.

Intravenous Somatic Gene Transfer with Antisense Tissue Factor Restores Blood Flow by Reducing Tumor Necrosis Factor-Induced Tissue Factor Expression and Fibrin Deposition in Mouse Meth-a Sarcoma.

Tissue Factor Controls the Balance of Angiogenic and Antiangiogenic Properties of Tumor Cells in Mice.

The angiogenic effect of tissue factor on tumors and wounds.

Comparison of Three Different Targeted Tissue Factor Fusion Proteins for Inducing Tumor Vessel Thrombosis.

Construction And Characterization Of A Truncated Tissue Factor-Coagulation-Based Composite System For Selective Thrombosis In Tumor Blood Vessels

Inhibitory Effect and Mechanism of Human Tumor Necrosis Factor-α Gene Transfected into Human Hepatoma Transplantation Tumor by LipofectamineTM 2000 in Nude Mice

Tumor-Specific Silencing of Tissue Factor Suppresses Metastasis and Prevents Cancer-Associated Hypercoagulability.

Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels.

Molecularly engineered truncated tissue factor with therapeutic aptamers for tumor-targeted delivery and vascular infarction

The Effect Of Human Tissue Factor Pathway Inhibitor-2 On The Growth And Metastasis Of Fibrosarcoma Tumors In Athymic Mice

A Recombined Fusion Protein SP5.2/tTF Induce Thrombosis in Tumor Blood Vessel.

Complete Regression of Established Murine Hepatocellular Carcinoma by in Vivo Tumor Necrosis Factor Alpha Gene Transfer

Regulation of vascular endothelial growth factor (VEGF) production and angiogenesis by tissue Factor (TF) in SGC-7901 gastric cancer cells.

Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)3 -tTF

Humanized Monoclonal Antibody TNT-3-mediated Truncated Tissue Factor for the Treatment of H22hepatoma-bearing Mice

Antitumor Effects of the Fibroblasts Transfected TNF-α Gene and Its Mutants

Prolonged and Effective Blockade of Tumor-Necrosis-Factor Activity Through Adenovirus-Mediated Gene-Transfer

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

Pathological Expression of Tissue Factor Confers Promising Antitumor Response to A Novel Therapeutic Antibody Sc1 in Triple Negative Breast Cancer and Pancreatic Adenocarcinoma

Soluble Fms-like Tyrosine Kinase-1 Expression Inhibits the Growth of Multiple Myeloma in Nude Mice

[Arginine-Glycine-aspartic Polypeptide Mediated Truncated Tissue Factor Therapy for Colorectal Carcinoma].